Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 968 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
McQuaid J. Asthma takes a hard toll on African-Americans. Can precision medicine ease the burden?. STAT Daily Recap 2019:26 de marzo. [Ref.ID 103064]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
White NJ. Tafenoquine - A radical improvement?. N Engl J Med 2019;380:17 de enero. [Ref.ID 103003]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-larp C, Chu CS, Villegas MF, Val F, Monteiro WM, Brito MAM, Costa MRF, Chuquiyauri R, Casapía M, Nguyen CH, Aruachan S, Papwijitsil R, Nosten FH, Bancone G, Angus B, Duparc S, Craig G, Rousell VM, Jones SW, Hardaker E, Clover DD, Kendall L, Mohamed K, Koh GCKW, Wilches VM, Breton JJ, Green JA. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019;380:17 de enero. [Ref.ID 103002]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, Yilma D, Pereira DB, Espino FEJ, Mia RZ, Chuquiyauri R, Val F, Casapía M, Monteiro WM, Brito MAM, Costa MRF, Buathong N, Noedl H, Diro E, Getie S, Wubie KM, Abdissa A, Zeynudin A, Abebe C, Tada MS, Brand F, Beck H-P, Angus B, Duparc S, Kleim J-P, Kellam LM, Rousell VM, Jones SW, Hardaker E, Mohamed K, Clover DD, Fletcher K, Breton JJ, Ugwuegbulam CO, Green JA, Koh GCKW. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019;380:17 de enero. [Ref.ID 103001]
5. Cita con resumen
Loftfield E, Cornelis MC, Caporaso N, Yu K, Sinha R, Freedman N. Association of coffee drinking with mortality by genetic variation in caffeine metabolism: findings from the UK biobank.. JAMA Intern Med 2018;178:1086-97. [Ref.ID 102776]
6.Enlace a cita original Cita con resumen
Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]
7. Cita con resumen
Greene JA, Loscalzo J. Putting the patient back together — Social medicine, network medicine, and the limits of reductionism. N Engl J Med 2017;377:2493-9. [Ref.ID 102185]
8. Cita con resumen
Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]
9.Tiene citas relacionadas Cita con resumen
Lee SWH, Chaiyakunapruk N, Lai NM. What G6PD-deficient individuals should really avoid. Br J Clin Pharmacol 2017;83:211-2. [Ref.ID 101931]
10.Tiene citas relacionadas Cita con resumen
Lee SWH, Lai NM, Chaiyakunapruk N, Chong DWK. Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review. Br J Clin Pharmacol 2017;83:172-9. [Ref.ID 101929]
11. Cita con resumen
Nembhard WN, Tang X, Hu Z, MacLeod S, Stowe Z, Webber D, the National Birth Defects Prevention Study. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. BMJ 2017;356:j832. [Ref.ID 101588]
12. Cita con resumen
Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]
13.Tiene citas relacionadas Cita con resumen
Ko TM, Tsai CY, Chen S-Y, Chen KS, Yu K-H, Chu C-S, Huang CM, Wang CR, Weng C-T, Yu C-L, Hsieh S-C, Tsai J-C, Lai W-T, Tsai W-C, Yin G-D, Ou T-T, Cheng K-H, Yen J-H, Liou T-L, Lin T-H, Chen D-Y, Hsiao P-J, Chen DY, Weng M-Y, Chen Y-M, Chen C-H, Liu F-M, Yen H-W, Lee J-J, Hung S-Y, Luo S-F, Yang Y-H, Chuang H-P, Chou Y-C, Liao H-T, Wang C-W, Huang C-L, Chen P, Wong C-S, Wu J-Y, Chen Y-T, Shen C-Y, for the Taiwan Allopurinol-SCAR Consortium. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848. [Ref.ID 99587]
14.Tiene citas relacionadas Cita con resumen
Li-Wan-Po A. Pharmacogenetics begins to deliver on its promises. BMJ 2015;351:h5042. [Ref.ID 99584]
15.Tiene citas relacionadas Cita con resumen
Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2280-7. [Ref.ID 99284]
16.Tiene citas relacionadas Cita con resumen
Mega JL, Stritziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015;385:2264-71. [Ref.ID 99283]
17.Tiene citas relacionadas
Schunkert H, Samani NJ. Statin treatment: can genetics sharpen the focus?. Lancet 2015;385:2227-9. [Ref.ID 99281]
18. Cita con resumen
Hampton T. New drug delivery technologies may advance personalized cancer therapy. JAMA 2015;313:2114. [Ref.ID 99118]
19.Tiene citas relacionadas Cita con resumen
Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret C, Van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, De Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, De Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsley JD, Chasman D, Ridker PM, Magglioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Forhage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hoogeveen A, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61. [Ref.ID 98804]
20.Tiene citas relacionadas Cita con resumen
Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet 2015;385:310-2. [Ref.ID 98803]
Seleccionar todas
 
 1 a 20 de 968 siguiente >>